Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,480.8
8.5 (0.35%)

 

  • STI Straits Times Index
    2,480.8
    8.5 (0.35%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,511.4
    2.2 (0.15%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,457.3
    221.9 (0.95%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,217.5
    -1.9 (-0.06%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,511.6
    307.0 (1.32%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    4,917.0
    -28.8 (-0.58%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 576.0M
  • Value: 601.1M
  • Rise: 129
  • Fall: 138
  • Unch: 513

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Jiutian Chemical0.053+0.002
Vicplas Intl0.365-0.085
Sembcorp Marine0.143+0.001
OEL0.019+0.001
HPH Trust USD0.136+0.006
Singtel2.120-0.020
Synagie0.205-0.005
Oceanus^0.007-
ISDN0.405+0.005
ThaiBev0.600+0.015

World Indices

World Indices
Name Last Change
Nasdaq 10,672.3 +39.3
HSI 23,235.4 -75.7
HSCEI 9,302.6 -68.6
Jakarta 4,945.8 +103.0
Nikkei 225 23,204.6 +116.8
SSE Comp 3,219.4 -3.8
Shanghai A 3,374.1 -4.0
Shanghai B 247.4 +0.8
KOSPI 2,278.8 +6.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Suntar Eco-City SUNTAR ECO-CITY LIMITED
Quotes 10 Minutes Delayed. Updated at 28 Sep 2020 07:12
Last (SGD): 0.695 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 0.695
Buy Price 0.695 Sell Price -
Buy Volume ('000) 20.0 Sell Volume ('000) -
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.00008 Trailing EPS (SGD) e 0.01463 NAV (SGD) b 0.2813
PE a 8687.500 Trailing PE f 47.514 Price / NAV b 2.4707
Dividend (SGD) d - Cash In Hand (SGD) g 0.0736 Issued & Paid-up Shares c 62,760,000
Dividend Yield (%) d - Price / Cash In Hand g 9.443 Treasury Shares h -
Beta - 75 Daysi -0.373 R-Squared - 75 Days(%)i 0.10 Market Cap (M) 43.618
Beta - 500 Daysi -0.299 R-Squared - 500 Days (%)i 0.29 Enterprise Value (M) 31.619
Piotroski F Score 5 Exchange Code BKZ Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 40.3441 6-Month VWAP 0.557 Free Float (%) -
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification China / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 17 Aug 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Suntar Eco-City SGX 43.618 8687.500 47.514 2.4707 -
Industry Biotechnology SGX 2,992.255 6.665 5.061 0.6303 4.749
China SGX 646.655 13.774 26.636 0.7266 3.584
Medical & Biotechnology SGX 919.105 21.694 20.942 1.3076 2.093
Local Peer Lonza SGX 5,940.891 6.617 5.028 0.6269 4.784
Global Peer AMGEN INC NASDAQ 142,803.911 18.210 19.565 13.3975 2.402
Global Peer AMGEN-T HKEx 1,083,533.900 17.635 19.045 13.1159 2.480
Global Peer CSL ASX 134,989.105 43.041 43.041 14.2384 0.989
Global Peer GILEAD SCIENCES INC NASDAQ 78,044.070 14.490 - 4.3293 4.088
Global Peer VERTEX PHARMACEUTICAL NASDAQ 69,852.040 59.357 33.570 9.2898 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 61,075.374 28.866 20.471 6.7431 -
Global Peer ILLUMINA INC NASDAQ 43,891.900 43.804 63.336 9.6191 -
Global Peer BIOGEN INC NASDAQ 43,263.777 7.347 7.300 3.8257 -
Global Peer SEATTLE GENETICS INC NASDAQ 32,180.745 - - 17.7395 -
Global Peer WUXI BIO HKEx 244,990.007 213.114 170.143 16.4005 -
Other Global Peers MODERNA INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), ALEXION PHARMACEUTICAL INC (NASDAQ), SINO BIOPHARM (HKEx), IMMUNOMEDICS INC (NASDAQ), INCYTE CORPORATION (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), 10X GENOMICS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), EXELIXIS INC (NASDAQ), NOVAVAX INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ALLOGENE THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), FIBROGEN INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), IMMUNOVANT INC (NASDAQ), GENSCRIPT BIO (HKEx), DECIPHERA PHARMACEUTICALS INC (NASDAQ), 3SBIO (HKEx), ALKERMES PLC (NASDAQ), VAXCYTE INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), VIVA BIOTECH (HKEx), XENCOR INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), HAOHAI BIOTEC (HKEx), BENITEC BIOPHARMA INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), EDITAS MEDICINE INC (NASDAQ), ALPHAMAB-B (HKEx), AURINIA PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), ALLOVIR INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), UNIQURE N.V. (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), VIELA BIO INC (NASDAQ), CORTEXYME INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), KYMERA THERAPEUTICS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), MACROGENICS INC (NASDAQ), COMPUGEN (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), EPIZYME INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), NGM BIOPHARMACEUTICALS INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), PRELUDE THERAPEUTICS INC (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), POLYNOVO LIMITED (ASX), NKARTA INC (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), FRONTAGE (HKEx), RETROPHIN INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), ALECTOR INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), AKOUOS INC (NASDAQ), PERSONALIS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), VAXART INC (NASDAQ), NANTKWEST INC (NASDAQ), ASCENTAGE-B (HKEx), PLIANT THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), AGENUS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), INHIBRX INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), KADMON HLDGS INC (NYSE), BIOCRYST PHARMACEUTICALS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), IMMATICS N V (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), OMEROS CORP (NASDAQ), PRECIGEN INC (NASDAQ), PASSAGE BIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), XBIOTECH INC (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), DPHARMA (Bursa), GERON CORP (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), HUMANIGEN INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), ATHIRA PHARMA INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), AVROBIO INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), IVERIC BIO INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), ATRECA INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), SINOMAB BIO-B (HKEx), KINTOR PHARMA-B (HKEx), CYMABAY THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), TREVENA INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), PROTHENA CORP PLC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), ATHERSYS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), ASCLETIS-B (HKEx), PREVAIL THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), LEE'S PHARM (HKEx), KAMADA (NASDAQ), PDL BIOPHARMA INC (NASDAQ), PANDION THERAPEUTICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), ESSEX BIO-TECH (HKEx), MERUS B V (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), TELIX PHARMACEUTIC (ASX), ASPIRA WOMENS HEALTH INC (NASDAQ), PFENEX INC (NYSE American), IMV INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), CHIASMA INC (NASDAQ), METACRINE INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), AFFIMED N V (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), CABALETTA BIO INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), LARIMAR THERAPEUTICS INC (NASDAQ), NEXTCURE INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), MEDICINOVA INC (NASDAQ), ADICET BIO INC (NASDAQ), VERASTEM INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), XOMA CORP (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), MEDICENNA THERAPEUTICS CORP (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), IBIO INC (NYSE American), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ADURO BIOTECH INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), OTONOMY INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CHIMERIX INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), NEXT SCIENCE LTD (ASX), GALECTIN THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), SESEN BIO INC (NASDAQ), IMUGENE LIMITED (ASX), AVEO PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), EQUILLIUM INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), BELLUS HEALTH INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CELYAD ONCOLOGY ADS EACH REPR 1 ORD (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), CEL-SCI CORP (NYSE American), GENOCEA BIOSCIENCES INC (NASDAQ), INFLARX N V (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), LUMOS PHARMA INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), WINDTREE THERAPEUTICS INC (NASDAQ), ORGENESIS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), PIERIS PHARMACEUTICALS INC (NASDAQ), EVOGENE LTD (NASDAQ), UNI-BIO GROUP (HKEx), X4 PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), NEUROBO PHARMACEUTICALS INC (NASDAQ), ANTEOTECH LIMITED (ASX), IMMUTEP LTD (ASX), BIONOMICS LTD (ASX), OUTLOOK THERAPEUTICS INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), BIONANO GENOMICS INC (NASDAQ), ARAVIVE INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), SYNLOGIC INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), SAVARA INC (NASDAQ), BIOVIE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), ANIXA BIOSCIENCES INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), COHBAR INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), CURIS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), MEMPHASYS LTD (ASX), MICROBOT MEDICAL INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), SOLIGENIX INC (NASDAQ), RECRO PHARMA INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), CT ENTERPRISE (HKEx), GENETIC TECHNOLOGIES (ASX), BIOTRON (ASX), MIRAGEN THERAPEUTICS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), OCUGEN INC (NASDAQ), PRECIPIO INC (NASDAQ), ATYR PHARMA INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), VACCINEX INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), REGENEUS LTD (ASX), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), PRESCIENT THERAPEUTICS LIMITED (ASX), BIOSINO BIO-TEC (HKEx), ORAGENICS INC (NYSE American), ACORDA THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), REGENT PACIFIC (HKEx), RHINOMED LIMITED (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ARCA BIOPHARMA INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ADVAXIS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), CONSTELLATION TECHNOLOGIES LTD (ASX), APTEVO THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), AIKIDO PHARMA INC (NASDAQ), ADALTA LTD (ASX), HISTOGEN INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), CYCLACEL PHARMACEUTICALS INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), ENDRA LIFE SCIENCES INC (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BIO-PATH HOLDINGS INC (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), PATRYS LIMITED (ASX), ITERUM THERAPEUTICS PLC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), PLUS THERAPEUTICS INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), CRYOSITE (ASX), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), XENETIC BIOSCIENCES INC (NASDAQ), SENESTECH INC (NASDAQ), NANOLLOSE LTD (ASX), LEAF RESOURCES LTD (ASX), HAO WEN HLDGS (HKEx), FACTOR THERAPEUTICS LIMITED (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), GEOVAX LABS INC (NASDAQ), ZAI LAB-SB (HKEx)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days ---
20 Days --0.005
-0.71 %
Medium Term Return 3 Months -+0.225
+47.87 %
6 Months -+0.385
+124.19 %
1 Year -+0.395
+131.67 %
Long Term Return 2 Years -+0.495
+247.50 %
3 Years -+0.420
+152.73 %
5 Years -+0.145
+26.36 %
Annualised Return Annualised --
+4.79 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.255 - 0.700 Change From 1 Year Low +0.440 % Change From 1 Year Low (%) +172.55
Change From 1 Year High -0.005 % Change From 1 Year High (%) -0.71
2 Years Range 0.100 - 0.700 Change From 2 Years Low +0.595 % Change From 2 Years Low (%) +595.00
Change From 2 Years High -0.005 % Change From 2 Years High (%) -0.71
5 Years Range 0.100 - 0.700 Change From 5 Years Low +0.595 % Change From 5 Years Low (%) +595.00
Change From 5 Years High -0.005 % Change From 5 Years High (%) -0.71
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Company was incorporated in Singapore on 22 September 2006 as a private limited company under the name Reyphon Agriceutical Pte Ltd. The Company was renamed to Reyphon Agriceutical Limited on 13 July 2007.
The Group's principal products are gibberellic acids, a plant growth regulator, and validamycin, a plant antibiotic. The Group also possess the know-how to produce fermentation-based pesticides. Its main product, gibberellic acids, is used in China mainly in the cultivation of hybrid rice, cotton, fruits and vegetables. Through active R&D, its objective is to widen the applications of gibberellic acids to cultivation of other plants such as tea plants, peanuts and soybean and lower its production costs and offer customers greater value with our gibberellic acids products.The Group manufactured, agriceutical products may be broadly classified into the following categories:-
(a) plant growth regulators;
(b) pesticides which include plant antibiotics, insecticide and weedicides; and
(c) fertilisers.

Its production facilities are located in Southern Industrial Development Zone of Xin?gan County, Jiangxi Province of China on a land area of approximately 65,002 sq m. Its products are sold throughout China such as Zhejiang, Fujian, Guangdong, Guangxi, Yunnan, Jiangsu, Shangdong, Hebei, Xinjiang, Anhui, Hainan, Hunan, Sichuan and Hubei. The Group also exports its products to countries such as United States, India, Turkey, Belgium, Canada, Germany, Malaysia, Pakistan, Spain, United Kingdom and Vietnam.

Change of Name:
Reyphon Agriceutical Limited to Suntar Eco-City Limited. Trading under the new name wef 14 June 2012.

Current core business of the Group has hereby expanded to include the eco-tourism real estate development and management business.

IPO Performance

Listing Date 01 Aug 2007 Full Subscription Rate (x) 13.55
No of Placement Shares (M) 76.60 No of Public Offer Shares (M) 2.00 Public Offer Subscription Rate (x) 494.05
IPO Price (SGD) a 1.950 First Day Close (SGD) a 3.050 First Week Close (SGD) a 2.500
Current vs IPO Price (%) -64.36 First Day Gain (%) +56.41 First Week Gain (%) +28.21
Notes:
  1. Adjusted for the following: Share Consolidation 1 for 5 on 19/11/2015

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2019 Dec 2019 Part 1(1.45 MB)
Annual Report 2018 Dec 2018 Part 1(3.17 MB)
Annual Report 2017 Dec 2017 Part 1(4.01 MB)
Annual Report 2016 Dec 2016 Part 1(1.06 MB)
Annual Report 2015 Dec 2015 Part 1(1.97 MB)
Annual Report 2014 Dec 2014 Part 1(1.50 MB)
Annual Report 2013 Dec 2013 Part 1(0.95 MB)
Annual Report 2012 Dec 2012 Part 1(0.51 MB)
Annual Report 2011 Dec 2011 Part 1(0.64 MB)
Annual Report 2010 Dec 2010 Part 1(0.85 MB)
Annual Report 2009 Dec 2009 Part 1(0.98 MB)
Annual Report 2008 Dec 2008 Part 1(1.53 MB)
Annual Report 2007 Dec 2007 Part 1(1.61 MB)
IPO Prospectus
IPO Prospectus 2007 Jul 2007 Part 1(3.22 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
25 Sep 2020 0.695 0.695 0.695 0.695 - -
24 Sep 2020 0.695 0.695 0.695 0.695 - -
23 Sep 2020 0.695 0.695 0.695 0.695 - -
22 Sep 2020 0.695 0.695 0.695 0.695 - -
21 Sep 2020 0.700 0.700 0.695 0.695 30,000 0.6967
18 Sep 2020 0.695 0.695 0.695 0.695 - -
17 Sep 2020 0.695 0.695 0.695 0.695 - -
16 Sep 2020 0.695 0.695 0.695 0.695 - -
15 Sep 2020 0.695 0.695 0.695 0.695 - -
14 Sep 2020 0.695 0.695 0.695 0.695 - -
11 Sep 2020 0.695 0.695 0.695 0.695 6,000 0.6950
10 Sep 2020 0.695 0.695 0.695 0.695 - -
09 Sep 2020 0.700 0.700 0.695 0.695 3,000 0.6967
08 Sep 2020 0.700 0.700 0.700 0.700 - -
07 Sep 2020 0.700 0.700 0.700 0.700 4,000 0.7000
04 Sep 2020 0.700 0.700 0.700 0.700 - -
03 Sep 2020 0.700 0.700 0.700 0.700 - -
02 Sep 2020 0.700 0.700 0.700 0.700 - -
01 Sep 2020 0.700 0.700 0.700 0.700 - -
31 Aug 2020 0.700 0.700 0.700 0.700 - -
28 Aug 2020 0.700 0.700 0.700 0.700 - -
27 Aug 2020 0.700 0.700 0.700 0.700 15,000 0.7000
Summary
Current 2 Weeks
(14 Sep 2020 to 25 Sep 2020)
0.695 0.700 0.695 0.695 30,000 -
Previous 2 Weeks
(31 Aug 2020 to 11 Sep 2020)
0.700 0.700 0.695 0.695 13,000 -
4 Weeks from
(30 Jul 2020 to 28 Aug 2020)
0.495 0.700 0.495 0.700 115,600 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.